Law360, New York (September 28, 2010, 1:31 PM ET) -- On Sept. 1, the U.S. Department of Justice announced the resolution of an investigation into alleged off-label marketing of Botox by Allergan Inc.
While Botox, an injectable botulinum toxin, is best known for smoothing facial frown lines, it is also indicated for treatment of "non-cosmetic" indications, such as strabismus, cervical dystonia and excess sweating. Allergan pled guilty to a one-count information charging the company with distribution of a misbranded drug pursuant to 21 U.S.C. ยง 331(a) and 352(f)(1), and paid fines and forfeiture totaling $375 million....
Botox Settlement Adds More Frown Lines To Industry
To view the full article, take a free trial now.
